Boundless Bio posted a GAAP net loss of $23.69 million for the quarter ended June 30, 2026, widening from $15.68 million a year earlier.
Operating loss widened to $24.38 million from $17.06 million, as total operating expenses climbed to $24.38 million from $17.06 million.
R&D expense rose to $13.97 million from $12.22 million; G&A jumped to $10.41 million from $4.84 million.
The company ended the quarter with $72.6 million in cash, cash equivalents and short-term investments, with no revenue reported.
Merger agreement and workforce reduction
Boundless Bio entered a merger agreement with Serapha on June 22, expects a $44 million to $48 million pre-closing cash dividend, and cut its workforce by about 75%.
BOLD•
